Ocular Therapeutix (OCUL) investor relations material

Executive summary

• SOL-1 trial demonstrated AXPAXLI's statistical superiority over approved anti-VEGF in wet AMD, with unmatched durability and disease control, maintaining vision in two-thirds of patients for a year with a single injection.

• SOL-X long-term extension trial initiated to evaluate AXPAXLI's outcomes over five years; SOL-R non-inferiority trial fully enrolled with topline data expected Q1 2027.

• HELIOS-3 Phase 3 trial in diabetic retinopathy ongoing, aiming for a broad label across diabetic retinal disease.

• AXPAXLI showed a strong safety profile with no treatment-related serious ocular or systemic adverse events.

• Commercial readiness is being accelerated, with infrastructure, payer engagement, and strategy refinement underway for a potential major retina therapy launch.

Financial highlights

• Ended Q1 2026 with $666.7 million in cash and cash equivalents, providing runway into 2028 and flexibility to advance NDA submission, complete ongoing trials, and accelerate commercial readiness.

• Net product revenue for Q1 2026 was $10.8 million, up 0.8% year-over-year, driven by DEXTENZA sales.

• Net loss for Q1 2026 was $(88.6) million, or $(0.40) per share, reflecting increased R&D and SG&A expenses.

• Research and development expenses rose to $66.2 million from $42.9 million year-over-year, mainly due to clinical trial progression.

• Weighted average shares outstanding increased to 224.1 million from 169.4 million year-over-year.

Outlook and guidance

• NDA submission for AXPAXLI in wet AMD planned based on SOL-1 week 52 data, leveraging the 505(b)(2) pathway for a potentially shortened review timeline.

• SOL-R topline data guidance accelerated to Q1 2027 due to rapid enrollment.

• Investor Day scheduled for June 17, 2026, to provide regulatory, program, and commercialization updates.

• Cash runway projected into 2028, excluding full commercialization expenses for AXPAXLI.

• Expect continued increases in R&D, SG&A, and pre-commercialization expenses for AXPAXLI and ongoing trials.